On July 23 and 24, 2026, a federal advisory committee voted to recommend six peptides for a list that would let compounding pharmacies work with them. The coverage that followed was loud, largely inaccurate, and almost entirely written as though the audience were men in recovery-focused fitness communities.
That is a strange omission, because two of the seven compounds reviewed were evaluated for conditions that fall disproportionately on women.
Here is what the vote was, what it changes, and the parts that actually concern female physiology.
What happened, briefly
The Pharmacy Compounding Advisory Committee reviewed seven peptides and recommended six of them for addition to the FDA's 503A Bulk Drug Substances List: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It declined to recommend emideltide, better known as DSIP.
The committee advises. It does not legislate, and it does not approve drugs. Its votes go to the FDA as recommendations the agency may accept, modify or ignore. Formal addition to the list requires notice-and-comment rulemaking, which has not started.
The one sentence to carry away
Nothing about your access changed in July. No peptide was approved, none became legal to compound, and any seller telling you otherwise is describing a regulation they have not read.
The two indications that should have led the coverage
Each peptide was reviewed for a specific use, chosen by the FDA for the purposes of the regulatory question. Those indications are not a menu of endorsed applications — but they do tell you what the agency was actually evaluating.
| Peptide | Indication reviewed | Outcome |
|---|---|---|
| MOTS-c | Obesity and osteoporosis | Recommended, 7–5 |
| BPC-157 | Ulcerative colitis | Recommended, 8–6 |
| KPV | Wound healing, inflammatory conditions | Recommended, 8–6 |
| TB-500 | Wound healing | Recommended, 8–6 |
| Epitalon | Insomnia | Recommended, 7–4 |
| Semax | Cerebral ischemia, migraine, trigeminal neuralgia | Recommended, 8–5 |
| Emideltide (DSIP) | Opioid withdrawal, insomnia, narcolepsy | Not recommended, 6–7 |
MOTS-c was reviewed for osteoporosis. Bone loss accelerates sharply after menopause, and osteoporosis is diagnosed in women far more often than in men. A mitochondrial-derived peptide going before a federal advisory committee partly on a bone endpoint is directly relevant to a female audience, and it went almost entirely unremarked.
Semax was reviewed partly for migraine. Migraine is roughly three times more common in women than men, with a well-documented hormonal component that most migraine research still handles poorly.
Two compounds were reviewed for insomnia — Epitalon, which passed, and DSIP, which did not. Sleep disruption is one of the most consistently reported symptoms of the menopause transition, and one of the least well served by existing options.
What this does and doesn't mean
An indication being reviewed is not an indication being endorsed. The FDA selected these uses for a narrow regulatory purpose: deciding whether a substance can be adequately characterized and safely handled in a compounding pharmacy. Nobody voted on whether MOTS-c helps bone density. That question remains open, and the human evidence is thin.
Marketing will now aim at you, and the aim will be off
The commercially useful thing about the July vote is that it produces a headline. Expect it attached to products it has nothing to do with.
The gap between the reviewed indication and the marketed claim is wide for nearly every compound on the list. BPC-157 was assessed for ulcerative colitis, not for joint repair. Epitalon was assessed for insomnia, not for telomere length — which is what it is almost universally sold on. Semax was assessed for cerebral ischemia and migraine, not for focus.
When you see the vote cited, the useful question is whether the seller names the indication the FDA reviewed, or the one their customers search for.
What the vote did not touch
GLP-1 medications. Semaglutide and tirzepatide were never part of this proceeding. They are approved drugs with an entirely separate regulatory history. Nothing in July applies to them.
Cosmetic peptides. The peptides in your serum are regulated under a different framework altogether. Matrixyl, argireline and the rest are not affected in any direction.
GHK-Cu — not yet. The copper peptide goes before the committee at a second meeting scheduled before the end of February 2027, along with cathelicidin LL-37, dihexa acetate, Melanotan II and PEG-MGF. For a female audience that is the meeting that matters more, and we cover it separately.
The evidence problem underneath all of this
There is a structural issue that no advisory vote addresses. Peptide research has historically been built on preclinical models and small early-phase studies that under-enrolled women, and in animal work frequently used male animals only.
The practical consequence is that even where a compound has published support, that support may not describe female physiology well. Effects that vary with estrogen and progesterone, with cycle phase, with the perimenopausal transition, or with hormonal contraception are largely uncharacterized for most of these molecules.
This is not a reason for alarm. It is a reason to treat confident female-specific claims about any of these compounds with more skepticism than the same claim made generally — because the data to support the specific version usually does not exist.
FDA scientists opposed all seven
Worth knowing, because it went nearly unreported: the agency's own reviewers recommended against including every one of the seven peptides, citing insufficient safety data, insufficient efficacy data and inadequate characterization of the molecules. The committee voted the other way six times. Whatever the July result signals, it is not an FDA safety endorsement.
If you are considering any of this
The regulated pathway and the research-chemical pathway are genuinely different things, and the distinction matters more than which compound you are interested in. A compounded preparation comes from a licensed pharmacy, against a prescription written for you specifically, using an active ingredient from an FDA-registered supplier. Research-use-only material comes with none of that and is not intended for human consumption.
Whatever the FDA eventually decides about the 503A list, that difference does not move.
Physician-led telehealth intake with medication dispensed by a licensed pharmacy against a patient-specific prescription. This is the regulated pathway, not a research-chemical order.
Start a consultation Paid link · Commission earnedWhere things stand
- Six peptides recommended, one declined. The vote is advisory and non-binding.
- Nothing is approved, and nothing became legal to compound.
- MOTS-c was reviewed partly for osteoporosis; Semax partly for migraine — both female-weighted conditions.
- The reviewed indications differ sharply from how these compounds are marketed.
- GHK-Cu goes before the committee before the end of February 2027.
Questions readers ask
No. An advisory committee recommended six for inclusion on a list of substances eligible for pharmacy compounding. That is a different process from drug approval, and the FDA has not acted on the recommendation. None of the six is an approved drug.
No. GLP-1 receptor agonists were never part of this proceeding. They are approved medications with a separate regulatory history, and nothing about the July meeting touches them.
Because one of the two indications the FDA reviewed it for was osteoporosis, a condition diagnosed far more often in women and one that accelerates after menopause. That said, being reviewed for an indication is not evidence that it works for it — the human data is limited.
Very little. Peptide research leans on preclinical models and small early-phase studies that under-enrolled women, and animal work has frequently used male animals only. Claims about how these compounds behave across the menstrual cycle, in perimenopause, or alongside hormonal contraception are mostly extrapolation.
None of these compounds has established safety data in pregnancy or lactation, and none is approved for any use. This is a conversation for an obstetric clinician, not for a vendor's FAQ page.
References
- US Food and Drug Administration. “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” Docket FDA-2026-N-2979. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” Client alert, July 27, 2026.
- Holland & Knight. “FDA Advisory Committee Endorses Compounding of Certain Peptides.” August 2026.
- Latham & Watkins. “FDA on Peptides: A New Landscape for Compounders.” 2026.
- Sheppard Mullin. “What to Watch: Status Update on Peptide Regulation.” June 2026.